Blue Jet Healthcare Ltd (BLUEJET) Q1 FY27 Earnings Call: Revenue Surges 118% YoY, Gross Margin Normalisation Path Outlined

Blue Jet Healthcare Ltd held its Q1 FY27 earnings call on August 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Performance and Key Metrics

• Q1 FY 2026-2027 revenue of Rs.3,548 million — up 4% sequentially and 118% year-on-year, driven by volume growth across PI, API and contrast media platforms.
• EBITDA of Rs.1,210 million (34.1% margin) — grew 173% YoY but declined 7% QoQ due to production phasing, inventory normalization and product mix. PAT was Rs.912 million, net margin 25.7%, up 148% YoY.
• Gross margin compressed 6.5% QoQ to 48.5% — CFO Ganesh Karupanil attributed ~4.4% to a Rs.75 crore finished goods inventory drawdown releasing prior-period overheads, and ~2.1% to product mix from higher PI/API contribution.
• Cash and treasury instruments of Rs.2.7 billion — Q1 CAPEX stood at Rs.280 million, with total committed capex of ~Rs.200 crore yet to be incurred for Unit Three, Mahad through FY 2026-2027.
• One-time GST demand of Rs.27 million — impacted EBITDA by 0.7%; lower forex gains from USD depreciation also weighed on profitability.

Gross Margin Pressure and Normalization Path

• Finished goods inventory declined ~Rs.75 crore in Q1 FY 2026-2027 — at cost plus allocated overheads, this released ~4.4% of previously-capitalized overheads into COGS, compressing gross margins. CFO confirmed raw material costs never exceeded 46-47% in prior quarters.
• Combined Q4 FY 2025-2026 & Q1 FY 2026-2027 gross margin of ~53% — management advised analysts to evaluate margins on a six-month cumulative basis to normalize the quarterly inventory mismatch; this back-calculated to 51.6% per the CFO.
• Inventory reduction was driven by customer dispatch schedules and logistics — not a conscious company decision. Management expects Q2 and Q3 FY 2026-2027 production to restore inventory to original levels.
• Management expects gross margin to sustain at ~53% — for the remaining quarters of FY 2026-2027 based on the current portfolio mix, excluding the one-off Q1 impact.
• Inventory days declined by 131 days — working-capital-to-turnover ratio improved, and inventory days are expected to remain in the current range going forward.
• Revenue recognition occurs upon customer delivery — goods in transit contributed to the quarterly mismatch; the make-to-order model means no seasonality or cyclicality in revenue patterns.

Contrast Media, PI & API, and Sweeteners

• Contrast media revenue of ~Rs.97 crore in Q1 FY 2026-2027 — below the prior quarterly run rate. Management cited three growth levers: largest customer forecasts, the iodinated product, and the intermediate for the gadolinium molecule.
• PI & API segment grew 8.2% QoQ — cardiovascular intermediate supply saw significant uptick vs Q1 FY 2025-2026. The bempedoic acid molecule (Esperion) is supported by active life-cycle management via new combination products.
• Artificial Sweeteners grew 17.4% QoQ — positioned with major FMCG clients; a new-generation sweetener addition is expected to boost segment turnover.
• Contrast media operates on a CDMO model — management reiterated it does not participate in the generic space. The iodinated intermediate facility is ready and will start supplying in Q2 FY 2026-2027 with "significant improvement" in net realization per kg.
• Full-year impact from the iodinated molecule expected in FY 2027-2028 — the NCM molecule is expected to grow in FY 2027-2028 and FY 2028-2029, with additional contrast media capacity opportunities from FY 2028-2029.
• Management cited the end formulation market for contrast media — growing from $6.7 billion to a projected $10 billion in the next few years, driving customer push for additional capacity.
• The analyst-referenced quarterly run rate of ~Rs.200 crore for bempedoic acid in Q1 FY 2026-2027 — management advised against extrapolating quarterly performance in a B2B CDMO business and declined specific guidance.

Mahad Unit, Land Parcel, and R&D Buildout

• Unit Three, Mahad commissioning on schedule for H1/H2 FY 2026-2027 — designed for continuous processing; capex revised from Rs.250 crore to ~Rs.300 crore due to added automation (Rs.100 crore incurred, balance Rs.200 crore to FY 2026-2027).
• New multi-purpose plant (~30 reactors) at Mahad and Hyderabad R&D center — targeting commissioning in H2 FY 2027-2028. The Hyderabad center will cost ~Rs.40 crore and focus on peptides, GLP-1 intermediates, and biocatalysis.
• Company surrendered an 8-acre land parcel in Gujarat — due to sub-scale; management is finalizing a much larger parcel for a new world-class CDMO facility to be developed in three phases.
• Phase-I includes four blocks — two for contrast media, one for a next-gen high-intensity sweetener, and one multi-purpose block. A further multipurpose block on the new land parcel is also planned.
• ~1,000 KL capacity addition planned over the next 2-3 years — no dedicated block for pharma intermediates in Phase-I, but a multipurpose block at Mahad will cater to this segment. Two new blocks are being added for contrast media based on customer lock-ins and contract visibility.
• Rs.400 million committed to R&D capabilities — in amino acid derivatives and D-state intermediates. A dedicated lab for peptide synthesis is being created within the new R&D center.
• Current overall capacity utilization is ~75% — the specific ~60% figure applies only to a particular PI segment block; management believes it can capture further demand upticks.

RFP Visibility, Peptide Fragments, and Client Lock-in

• CDMO RFP pipeline stood at ~20 projects as of Q1 FY 2026-2027 — with 6 in late-stage (Phase 3/commercial), up from 11-12 projects in FY 2025-2026. Growth was driven partly by new opportunities in peptide fragments and continued traction in the chronic disease space.
• 45 peptide fragments developed with high client conviction — CEO VK Singh stated the company has been working on peptide fragment chemistry for the last 2-2.5 years with a dedicated team. All 45 fragments are ready for near-immediate commercialization based on expressed customer interest, not speculative "blue-sky" development.
• Focus is on amino acid derivatives and intermediates to end peptides — including GLP-1 products, with conversations underway with certain innovator companies. Near-term capacity will be served from the multipurpose plant at Unit Two.
• Management stated per KL and per KG realizations have risen significantly — as the company moved from building blocks to advanced intermediates (one or two steps short of final API) for both Contrast Media and PI segments.
• Extension to APIs would be logical but only with specific client lock-in — MD Shiven Arora clarified the company does not wish to participate in the generic space. Environmental clearance for the new Mahad unit includes a laundry list of products (e.g., an API for bentoproic acid) to avoid future amendments; this does not indicate near-term API capacity addition.
• Management is not pursuing fermentation-based amino acids or a broad library of hundreds of fragments — the peptide strategy is targeted and conviction-driven.

Guidance, Growth Levers, and Risk Factors

• Management kept guidance for FY26 (current year) unchanged — expressed confidence in achieving FY26 goals, citing demand visibility across key customers, capacity in place, and expanding product pipelines.
• Structural tailwinds cited by management — global innovator supply chain de-risking (China-plus-one), increasing adoption of complex APIs and NCE intermediates, and growing traction in contrast media via new molecules under validation.
• Contrast media business aspires to return to FY 2025-2026 revenue levels — three growth levers: largest customer forecasts, iodinated product, and gadolinium molecule intermediate. Full-year iodinated impact in FY 2027-2028.
• Cardiovascular PI API realizations stable in Q1 FY 2026-2027 — management expects to maintain the annual revenue run rate achieved in FY 2025-2026 with some growth in FY 2026-2027; margins expected to remain intact under the current cost structure.
• Company-level net block asset turnover >4x — management guided long-term gross block asset turnover of ~2.5 to 3x over the next five years (FY 2026-2027 to FY 2030-2031), supported by planned expansion at the Oakhley facility.
• Fundraise plans remain in the "drawing room stage" — only a shareholder resolution has been taken; options are still being evaluated. No timeline or quantum disclosed.
• Management cautioned that a single quarter is not a reliable indicator for a B2B CDMO business — new product launches expected in Q2 and Q3 FY 2026-2027 include an iodinated ABAC intermediate and backward integration initiatives within contrast media.